Investment Analysts’ Recent Ratings Updates for Oric Pharmaceuticals (ORIC)

Oric Pharmaceuticals (NASDAQ: ORIC) has recently received a number of price target changes and ratings updates:

• 3/13/2026 – Oric Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock.
• 3/9/2026 – Oric Pharmaceuticals had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 2/28/2026 – Oric Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/24/2026 – Oric Pharmaceuticals had its price target raised by Citigroup Inc. from $16.00 to $17.00. They now have a “buy” rating on the stock.
• 2/24/2026 – Oric Pharmaceuticals had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $15.00 price target on the stock.
• 2/24/2026 – Oric Pharmaceuticals had its price target raised by HC Wainwright from $23.00 to $25.00. They now have a “buy” rating on the stock.
• 2/24/2026 – Oric Pharmaceuticals had its “outperform” rating reaffirmed by Wedbush. They now have a $20.00 price target on the stock.
• 1/22/2026 – Oric Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/13/2026 – Oric Pharmaceuticals had its “outperform” rating reaffirmed by Wedbush. They now have a $20.00 price target on the stock.

Insider Buying and Selling at Oric Pharmaceuticals

In related news, insider Pratik S. Multani sold 10,720 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total value of $97,123.20. Following the completion of the sale, the insider directly owned 68,149 shares in the company, valued at approximately $617,429.94. The trade was a 13.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jacob Chacko sold 33,374 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total transaction of $302,368.44. Following the sale, the chief executive officer directly owned 581,711 shares of the company’s stock, valued at approximately $5,270,301.66. This represents a 5.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 106,814 shares of company stock worth $1,199,135 over the last ninety days. 6.82% of the stock is currently owned by insiders.

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.